These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 36769308)
41. Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure. Oliveros E; Oni ET; Shahzad A; Kluger AY; Lo KB; Rangaswami J; McCullough PA Cardiorenal Med; 2020; 10(2):69-84. PubMed ID: 32062648 [TBL] [Abstract][Full Text] [Related]
42. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus. Wish JB; Pergola P Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502 [TBL] [Abstract][Full Text] [Related]
43. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364 [TBL] [Abstract][Full Text] [Related]
44. [Renal insufficiency in the context of cardio-pulmonary-renal pathophysiology]. Schwenger V; Emrich IE; Mahfoud F; Latus J; Remppis A Internist (Berl); 2021 Nov; 62(11):1153-1165. PubMed ID: 34605971 [TBL] [Abstract][Full Text] [Related]
45. Renin-angiotensin-aldosterone system inhibitors in heart failure. Shearer F; Lang CC; Struthers AD Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393 [TBL] [Abstract][Full Text] [Related]
46. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2. Packer M; Kitzman DW JACC Heart Fail; 2018 Aug; 6(8):633-639. PubMed ID: 29525327 [TBL] [Abstract][Full Text] [Related]
47. Medical Therapies for Heart Failure With Preserved Ejection Fraction. Kjeldsen SE; von Lueder TG; Smiseth OA; Wachtell K; Mistry N; Westheim AS; Hopper I; Julius S; Pitt B; Reid CM; Devereux RB; Zannad F Hypertension; 2020 Jan; 75(1):23-32. PubMed ID: 31786973 [TBL] [Abstract][Full Text] [Related]
48. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries. Rossignol P; Zannad F; Pitt B; Int J Cardiol; 2014 Dec; 177(3):731-3. PubMed ID: 25465821 [TBL] [Abstract][Full Text] [Related]
49. [Current options for slowing the progression of chronic kidney disease]. Tesař V Vnitr Lek; 2022; 68(7):420-424. PubMed ID: 36402565 [TBL] [Abstract][Full Text] [Related]
51. Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. Chow C; Mentz RJ; Greene SJ Curr Heart Fail Rep; 2021 Jun; 18(3):132-143. PubMed ID: 33835396 [TBL] [Abstract][Full Text] [Related]
52. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849 [TBL] [Abstract][Full Text] [Related]
53. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829 [TBL] [Abstract][Full Text] [Related]
54. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings. Książczyk M; Lelonek M Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710 [TBL] [Abstract][Full Text] [Related]
55. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs. Ferreira JP; Pitt B; McMurray JJV; Pocock SJ; Solomon SD; Pfeffer MA; Zannad F; Rossignol P JACC Heart Fail; 2022 Nov; 10(11):842-850. PubMed ID: 36328653 [TBL] [Abstract][Full Text] [Related]
56. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives. Llubani R; Vukadinović D; Werner C; Marx N; Zewinger S; Böhm M Curr Heart Fail Rep; 2018 Dec; 15(6):390-397. PubMed ID: 30421355 [TBL] [Abstract][Full Text] [Related]
57. Progress in the management of patients with diabetes and chronic kidney disease. Pozo Garcia L; Thomas SS; Rajesh H; Navaneethan SD Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):456-463. PubMed ID: 35894280 [TBL] [Abstract][Full Text] [Related]
58. Drug therapies in chronic heart failure: a focus on reduced ejection fraction. Bolam H; Morton G; Kalra PR Clin Med (Lond); 2018 Mar; 18(2):138-145. PubMed ID: 29626018 [TBL] [Abstract][Full Text] [Related]
59. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease. Tsujimoto T; Kajio H Eur J Prev Cardiol; 2018 Aug; 25(12):1268-1277. PubMed ID: 29808753 [TBL] [Abstract][Full Text] [Related]
60. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]